



Revenio Group Corporation's Interim Report January 1-June 30, 2014: Q2 IN LINE WITH EXPECTATIONS - NET SALES UP, OPERATING RESULT REMAINED AT THE PREVIOUS YEAR'S LEVEL

Revenio Group Corporation Stock Exchange Release 4 August 2014 at 09:00 hrs.

Revenio Group Corporation's Interim Report January 1-June 30, 2014: Q2 IN LINE WITH EXPECTATIONS - NET SALES UP, OPERATING RESULT REMAINED AT THE PREVIOUS YEAR'S LEVEL

Highlights for April-June, 2014:

- * The Group's net sales were 6.8 MEUR (6.4), growth 6.2 % and operating profit 1.4 MEUR (1.5), decrease 2.3 %.
- * Revenio Health Tech segment net sales grew by 10.6%. Investments made in accordance with the strategy in research and development as well as in marketing and approval processes increased costs. For this reason, the segment's operating profit decreased compared to the second quarter of 2013 and was EUR 1.1 (1.3) million.
- * Probe sales grew strongly, with an increase of 35.0% compared to the second quarter of 2013.
- * Demand for Health Tech segment products was high especially in the UK, Japan, Australia, Scandinavia, Germany and Russia.
- * Sales of tonometers designed for veterinarians grew strongly with an increase of 23.6% compared to the second quarter of 2013.
- * Despite the macroeconomic challenges, the Revenio Technology and Services segment performed reasonably well in the first half of the year. The segment's net sales were up 1.8% compared to the second quarter of 2013. Operating profit grew significantly, with an increase of 53.3% compared to the second quarter of 2013. Operating profit was boosted especially by the successful actions taken to improve the efficiency of the production of Boomeranger Boats, which are part of the Rigid Inflatable Boats business.
- * The growth of sales in Health Tech is estimated to be stronger in the second half of the year than the growth achieved during the first half of the year.
- * The Group's financial guidance for 2014 remains unchanged:
Net sales and operating profit of continuing operations exclusive of non-recurring items are expected to see year-on-year growth. The biggest growth is seen in the Health Tech segment. The risks posed by growth in the Technology and Services segment have increased due to economic uncertainty.

Highlights for January-June 2014:

- * The development in the Revenio Health Tech segment continued to be positive despite the significant investments in future growth. The segment's net sales were EUR 7.3 (6.4) million, an increase of 14.4%. Operating profit was EUR 2.5 (2.4) million, an increase of 1.7%.
- * Net sales of the Revenio Technology and Services segment decreased to EUR 5.8 (6.4) million, a decrease of 9.6% compared to the first half of 2013. Operating profit grew to EUR 0.6 million (0.5), an increase of 9.9%.
- * The Annual General Meeting held on March 20, 2014 decided to distribute a dividend of EUR 0.30 (0.20) per share.
- * The Annual General Meeting elected Kyösti Kakkonen, LL.B. and Pekka Rönkä, M.Sc. as new members of the Board of Directors.

Group key figures:

April-June 2014

- * Net sales were EUR 6.8 (6.4) million, an increase of 6.2%
- * Operating profit was EUR 1.4 (1.5) million, or 21.2 (23.0) percent of net sales, a decrease of 2.3%.
- * Net sales of the Revenio Health Tech segment totaled EUR 3.6 (3.2) million, an increase of 10.6%.
- * Operating profit of the Revenio Health Tech segment amounted to EUR 1.1 (1.3) million, representing 30.0 (40.1) percent of net sales, a change of EUR -0.2 million, a decrease of 17.2%.
- * Net sales of the Revenio Technology and Services segment totaled EUR 3.2 (3.1) million, a change of EUR 0.1 million and an increase of 1.8%.
- * Operating profit of Revenio Technology and Services amounted to EUR 0.5 (0.4) million, representing 17.3 (11.5) percent of net sales, a change of EUR 0.2 million, an increase of 53.3%.
- * The net result for discontinued operations was EUR -0.1 (0.0) million.
- * Diluted and undiluted earnings per share were EUR 0.16 (0.13).

January-June 2014

- * Net sales were EUR 13.0 (12.7) million, an increase of 2.3%
- * Operating profit was EUR 2.6 (2.6) million, or 20.0 (20.3) percent of net sales, an increase of 0.9%
- * Net sales of the Revenio Health Tech segment totaled EUR 7.3 (6.4) million, a change of EUR 0.9 million, an increase of 14.4%.
- * Operating profit of the Revenio Health Tech segment amounted to EUR 2.5 (2.4) million, representing 34.2 (38.5) percent of net sales, a change of EUR 0.1 million, an increase of 1.7%.
- * Net sales of the Revenio Technology and Services segment totaled EUR 5.8 (6.4) million, a change of EUR -0.6 million, a decrease of 9.6%.
- * Operating profit of Revenio Technology and Services segment amounted to EUR 0.6 (0.5) million, representing 10.4 (8.6) percent of net sales, a change of EUR 0.1 million, an increase of 9.9%.
- * The net result for discontinued operations was EUR -0.1 (0.0) million.
- * Pre-tax profit, continuing operations, EUR 2.6 million (2.6).
- * Undiluted earnings per share, continuing operations EUR 0.30 (0.24).
- * Diluted earnings per share, continuing operations EUR 0.30 (0.24).
- * Cash flow from continuing operations EUR 1.7 (2.7) million.

Olli-Pekka Salovaara, President & CEO:

"The investments in our Health Tech segment, which were made in accordance with our strategy, are proceeding according to plan and are visible as an increase in costs in the second quarter. These development projects are very important to the growth of our Health Tech segment in the coming years. Our investments in research and product development as well as sales and marketing are among the largest in the history of the Revenio group.

The growth of net sales in our Health Tech segment was not quite what we are used to. This is due to the state of confusion in our main market in the US that was caused to our customers by president Obama's health care system's renewal process. The dip caused by the renewal has been publically recognized and experienced also by other Health Tech companies in the US marketplace. However, the situation has settled down and the future is again clearer. In line with the seasonality that is typical for our Health Tech segment, the sales focuses towards the end of the year.

The research and development projects that we launched have already yielded several interesting development ideas, the potential of which we will be studying during the upcoming months.

In June, the new Icare HOME tonometer was completed and the sales activities were started in Europe and Asia. The feedback we have received has been very encouraging. The sales activities of the new product are initially focused on the local studies and tests carried out by leading universities and ophthalmologists. In the US, we are still collecting clinical test results that are needed as an attachment to the FDA application. Test subjects for these clinical tests are required to meet strict criteria and have certain IOP, and the effort required to find suitable test subjects has been greater than anticipated. Despite measures to improve the efficiency of the process, the daily number of patients meeting the exact criteria has been smaller than expected and for this reason this phase, which is essential to the approval process, will take longer than anticipated. When the tests are completed, we will submit the application to the FDA.

Important for future growth is also that during the review period, we started sales of the first serially manufactured Oscare Medical osteoporosis measurement devices. In addition, we are already in the process of actively building the distribution network in various countries.

As expected, the net sales of our Technology and Services segment were lower than in the first half of 2013. However, there was a significant increase in operating profit, which was mainly due to the actions taken to improve the efficiency of the production of Boomeranger Boats, which are part of the Rigid Inflatable Boats business. The Technology and Services business segment is still sensitive to the general uncertainty prevailing in the market."

APRIL-JUNE 2014 COMMENTS:

REVENIO HEALTH TECH

Icare Finland Oy, which represents the Revenio Health Tech segment, had its operational focus on global sales efforts, new research and development projects as well as new sales opportunities, such as launching the Icare HOME tonometer. The device received a CE marking in June. The Icare HOME tonometer, which is designed to be used on the recommendation of an ophthalmologist as part of the treatment process for self-monitoring of intraocular pressure is expected to be a significant future growth area for Icare. Intraocular pressure may vary significantly during the day. According to various clinical studies, IOP is often higher during the night. Therefore, collecting IOP information during different times of the day facilitates and specifies the work of the doctor making the diagnosis. For the patient who needs several measurements during the day, home monitoring is also financially more appealing than a stay at hospital. Now, the doctors can lend patients a tonometer to be used at home as part of the treatment process.

In the United States, the clinical studies related to the FDA approval process have proceeded according to the plan, even though it was challenging to find test subjects who met the strict criteria, especially in relation to intraocular pressure. The daily number of patients at the Johns Hopkins Hospital has been lower than estimated and for this reason the study has progressed slower than anticipated. Clinical trials are an important part of the FDA approval process and that is why we want to invest in them. Once the studies have been completed, we will submit an application to the FDA.

In April-June, 2014, the sales of Revenio Health Tech segment were EUR 3.6 (3.2) million, growing by 10.6 % compared to the second quarter of 2013. Operating profit was EUR 1.1 (1.3) million, which, as expected, was lower than the operating profit in the second quarter of 2013. This was due to the development projects that were implemented according to the strategy. The research and development projects have already yielded interesting development ideas, the potential of which we will be studying during the upcoming months.

In general, the market situation was good, especially in the UK, Japan, Australia, Scandinavia, Germany and Russia. During the review period, it became evident that there are certain challenges related to political changes in health-care in the United States. However, we are convinced that the challenges posed by the political change in the market are temporary. There have been no changes in the competition and, according to the numerous signals we have received, the entire industry has experienced similar challenges during the first months of the year. We have taken actions to boost sales operations in the United States, and are, among other things, increasing our sales power in this market, as well as assessing the possibilities of a variety of commercial partnerships with leading companies in this sector.

After the review period, as part of the intensification of the US sales and marketing efforts, we have made the decision to open our own office in North Carolina during the fall of 2014. With these measures we will ensure Icare a strong foothold in the US market, and build the future growth.

The sales of the Icare VET tonometer, which is designed for measuring the intraocular pressure in animals, were up 23.6% year-on-year. This product group showed strong growth during the period, especially in the United States and Europe.

Probe sales increased by 35.0% and in the future the importance of this market is expected to grow even further. The increased use of devices, the increased number of patient-oriented screenings, and the change in the user-profile of the devices are boosting the growth of probe sales. Towards the end of the year, the transfer of the central phases of probe production to Finland is expected to have a positive effect on the probe production process, capacity and margin

structure.

In June, the Icare HOME was presented in Nice and Hong Kong to partners and glaucoma specialists. The reception was very positive and the doctors were extremely interested in our concept. We will continue to market the product this fall by participating in the industry's major conferences and by taking part in local and international studies.

In recent years, there has been a growing commercial and clinical interest in around-the-clock measurement of intraocular pressure that the patient can perform at home in their normal environment, and, based on the feedback we have received, we believe our concept is an extremely competitive solution to cover this need.

During this period, we started sales of the first serially manufactured Oscare Medical osteoporosis measurement devices. At the same time, we mapped target customer segments and started to build a distribution network. In addition, training of the first distributors outside Finland was started, and we established relationships to opinion leaders central to the development of our business. Clinical studies in Finland proceeded in accordance with the plan and the initial results support our previous understanding of the device benefits in bone health screening. The Oscare Medical web site as well as the marketing material were updated and we introduced the slogan "Better Bone Health - Better Life".

REVENIO TECHNOLOGY AND SERVICES

During the period, the business areas in Revenio's Technology and Services segment included the following: Contact Center business, Rigid Inflatable Boats business and Software business.

In line with its strategy, the Revenio Technology and Services segment focuses on maintaining a good profitability trend, organic growth and efficiency. The segment's operating activities are sensitive to the general economic developments, which is why the Revenio Group's guidance for 2014 states that the risks related to the segment's business are higher due to the economic uncertainty.

In April-June 2014, the segment recorded net sales of EUR 3.2 (3.1) million, an increase of 1.8% compared to the second quarter of 2013. Operating profit increased substantially and was EUR 0.5 million (0.4), growing by 53.3% year-on-year. The operating result was significantly affected by the measures taken to increase the production efficiency of the Rigid Inflatable Boats business and the increased profitability obtained by these actions.

Contact Center business

The net sales of the Contact Center business increased year-on-year, but as a result of the business development actions taken during the first months of the year, operating profit fell slightly. The demand for professional services remained good, despite the challenging market conditions in the industry. Midas Touch, which represents the Contact Center business, has invested, in particular, in the quality of the services it provides and in customer service excellence, which has brought the company major new projects and customers.

Rigid Inflatable Boats business

Boomeranger Boats Oy, which represents the Rigid Inflatable Boats business, increased both its net sales and operating profit. The main reasons for this were the timing of project deliveries, which took place during the review period, and measures to improve production efficiency. The operating model of small, customer-specific production batches, which earlier presented challenges, has been modified in order to make serial manufacturing more possible.

Software business

The net sales and operating profit of Done Software Solutions Oy, which represents the software business, fell slightly compared to the second quarter of 2013. The business environment has become more challenging because of the general economic situation. However, even in challenging times, it is estimated that companies will still invest in their internal logistics in order to improve their production and economic efficiency. During the review period, the Software business focused on growth in the small-scale development and expansion projects for current customers.

Total					2.6 20	2.6 20
-------	--	--	--	--	--------	--------

The net sales, margin, and profit, by segment and quarter

, excluding non-recurring items, were as follows:

MEUR	Q2/14	Q1/14	Q4/13	Q3/13	Q2/13	Q1/13
Net sales:						
Revenio Health Tech	3.6	3.7	4.1	3.0	3.2	3.1
Revenio Technology and Services	3.2	2.6	3.0	2.8	3.1	3.3
Total	6.8	6.2	7.1	5.8	6.3	6.4
Segment profit margin:						
Revenio Health Tech	1.1	1.4	1.7	1.2	1.3	1.1
Revenio Technology and Services	0.5	0.1	0.2	0.4	0.4	0.2
Total	1.6	1.5	1.9	1.6	1.7	1.3
Parent co. expenses	-0.2	-0.3	-0.2	-0.2	-0.2	-0.2
Operating profit	1.4	1.2	1.7	1.4	1.4	1.1
Operating profit-%	21	19	20	22	20	18

PERSONNEL

During the review period, the number of personnel employed by the Group in continuing operations averaged 208 (212). At the end of the period, the number of employees stood at 226 (230).

Average no. of employees by segments:

	30 June 2014	30 June 2013	Change
Revenio Health Tech	24	17	7
Revenio Technology and Services	179	191	-12
Parent Company	5	4	1
Group Total	208	212	-4

Wages, salaries, and other remuneration paid for continuing operations during the period totaled EUR 3.7 million (3.6).

SHARES, SHARE CAPITAL AND MANAGEMENT HOLDINGS

On June 30, 2014, the Revenio Group Corporation's fully paid-up share capital registered with the Trade Register was EUR 5,314,918.67 and the number of shares totaled 7,883,019.

During the review period, the number of shares increased by 32,540 following subscriptions made on the basis of the 2007 stock option scheme. Series 2007A option rights were used to subscribe for 0 shares, 2007B option rights to

subscribe for 19,540 shares and 2007C options rights to subscribe for 13,000 shares. The subscription period for 2007A options ended on May 1, 2013. The outstanding 2007B and 2007C options can be used to subscribe for a total of 92,390 shares until the close of the subscription period on November 1, 2014 (2007B) and May 1, 2016 (2007C).

The company has one class of share, and all shares confer the same voting rights and an equal right to dividends and the company's funds. On June 30, 2014, the President & CEO, members of the Board of Directors and their closely related parties held 11.9% of the company's shares (936,798 shares) and 0% of the option rights.

CHANGES IN SHAREHOLDING

On March 26, 2014, it was announced that Eyemaker's Finland Oy's share of the total number of shares and voting rights in Revenio Group Corporation had fallen under one twentieth (1/20). Eyemaker's Finland Oy now holds 4.45% of the shares and voting rights in Revenio Group Corporation. Eyemaker's Finland Oy owns 350,000 shares in Revenio Group Corporation.

CURRENT OPTION RIGHTS

The company has a corporate option scheme that began in 2007. On the basis of the share issue authorization approved by the Annual General Meeting of April 3, 2007, the Board of Revenio Group Corporation decided, on November 23, 2007, on a new corporate option scheme comprising a maximum of 3,684,365 option rights. Ten option rights entitle the holder to subscribe for one (1) Revenio Group Corporation share. On June 30, 2014, the proportion of shares that can still be subscribed for on the basis of the option rights issued represented a maximum of 1.2 percent of the company's shares and votes, once all new shares subscribed for with these option rights have been registered. New shares subscribed for via the option program entitle the holder to a dividend from the subscription year onwards.

The option rights have been divided into three series: Series A (1,684,365), Series B (1,000,000) and Series C (1,000,000). The subscription periods are as follows: Series A, May 1, 2009-May 1, 2013, Series B, November 1, 2010-November 1, 2014, and Series C, May 1, 2012-May 1, 2016. The share subscription price will be the trade-weighted average price during the period November 1-30, 2007 multiplied by ten (EUR 5.99, Series A), April 1-30, 2009 multiplied by ten (EUR 1.75, Series B), and November 1-30, 2010 multiplied by ten (EUR 1.69, Series C). No new options were issued to the personnel during the review period.

TRADING ON NASDAQ OMX HELSINKI

During January 1-June 30, 2014, the Revenio Group Corporation's share turnover on the NASDAQ OMX Helsinki exchange totaled EUR 22.8 (11.3) million, representing 1.6 (1.7) million shares or 20.4% (22.2) of all shares outstanding. The highest trading price was EUR 17.20 (8.10) and the lowest EUR 11.32 (4.10). At the end of the review period, the closing price was EUR 15.95 (7.55), and the average share price EUR 14.22 (6.48). The Revenio Group Corporation's market value stood at EUR 125.7 million (59.2) on 6/30/2014.

RISK MANAGEMENT

The Group's major business risks are presented in its financial statement bulletin of 2/12/2014. No changes in these risks have occurred since the release of the bulletin.

ANNUAL GENERAL MEETING AND BOARD AUTHORIZATIONS IN EFFECT

The Annual General Meeting held on 3/20/2014 approved the company's financial statements and discharged the President & CEO and the members of the Board of Directors from liability for the financial year January 1-December 31, 2013.

The Annual General Meeting decided to elect five members to the Board of Directors. Rolf Fryckman, Ari Kohonen and Pekka Tammela were re-elected as Board members, and Kyösti Kakkonen and Pekka Rönkä were elected as new members. At its organization meeting, held after the Annual General Meeting, the Board of Directors re-elected Pekka Tammela as Chairman.

The AGM decided that the Chairman of the Board should be paid a fee of EUR 36,000 per annum and other Board members EUR 18,000 per annum. A total of 40

percent of Board members' emoluments will be settled in the form of company shares, while 60 percent will comprise a monetary payment.

The AGM re-elected PricewaterhouseCoopers Oy, Authorized Public Accountants, as the company's auditors with Juha Tuomala, Authorized Public Accountant, as principal auditor.

The AGM accepted the Board's proposal on profit distribution, according to which the parent company's net result for the financial period, EUR -304,972.66, will be added to retained earnings, and a dividend of EUR 0.30 per share will be paid.

The Annual General Meeting rescinded the earlier authorization to buy back 771,107 of the company's own shares, and authorized the Board of Directors to buy back a maximum of 785,047 of the company's own shares following the approval of the reverse share split, either in one or several installments, using the company's unrestricted equity, in which case any buyback will reduce the amount of distributable earnings. The company may buy back shares in order to develop its capital structure, in order to finance and implement any corporate acquisitions or other transactions, and to implement share-based incentive plans or otherwise dispose of or cancel them. This authorization is valid until 4/30/2015.

The AGM authorized the Board of Directors, following the approval of the reverse share split, to decide on the issuance of a maximum of 3,000,000 shares or to grant special rights (including stock options) conferring entitlement to shares, as referred to in Section 1 of Chapter 10 of the Limited Liability Companies Act, in one or several tranches. This authorization was granted for the purpose of financing and implementing any prospective corporate acquisitions or other transactions, implementing the company's share-based incentive schemes, or for other purposes determined by the Board.

This authorization is valid until 4/30/2015. This authorization shall supersede the authorization to decide on a share issue and on the granting of special rights giving entitlement to shares granted at the AGM of March 21, 2013.

BOARD OF DIRECTORS AND AUDITORS

As of March 21, 2014, the Revenio Group Corporation's Board of Directors has consisted of: Pekka Tammela, M.Sc. (Econ.), Authorized Public Accountant, partner in PJ Maa Partners Oy (Chairman); Rolf Fryckman, optician, Chairman of the Board of Eyemaker's Finland Oy; Ari Kohonen, M.Sc. (Eng.), M.Sc. (Econ.), Chairman of the Board of Gerako Oy; and, as new members, Kyösti Kakkonen, LL.B., Chairman of the Board of Joensuun Kauppa ja Kone; and Pekka Rönkä, M.Sc. (Eng.).

PricewaterhouseCoopers Oy, Authorized Public Accountants, serves as the company's auditor, with Juha Tuomala, Authorized Public Accountant, as principal auditor.

MAJOR EVENTS AFTER THE REVIEW PERIOD

There have been no major events since the end of the review period.

OUTLOOK FOR 2014

Net sales and operating profit of continuing operations exclusive of non-recurring items are expected to see year-on-year growth. The biggest growth is foreseen in the Health Tech segment. The risks posed by growth in the Technology and Services segment have increased due to financial uncertainty.

STATEMENT OF ACCOUNTING POLICIES

This interim report has been prepared in compliance with the requirements of IAS 34 Interim Financial Reporting. The figures are unaudited.

GROUP KEY FIGURES AND RATIOS (MEUR)	1-6/2014	1-6/2013	1-12/2013
Net sales, continuing operations	13.0	12.7	25.7
Ebitda, continuing operations	2.9	2.9	6.3
Ebitda-%, continuing operations	22.3	22.9	24.3

Operating profit, continuing operations	2.6	2.6	5.6
Operating profit-%, continuing operations	20.0	20.3	21.7
Pre-tax profit, continuing operations	2.6	2.6	5.5
Pre-tax profit-%, continuing operations	20.1	20.2	21.3
Net profit from discontinued operations	-0.1	0.0	0.0
Net profit, continuing operations	2.3	1.9	4.3
Net profit-%, continuing operations	18.0	12.4	16.7
Gross capital expenditure	0.6	0.3	0.9
Gross capital expenditure-%	9.2	2.0	3.5
R&D costs	0.6	0.1	0.9
R&D costs-% from net sales	4.7	1.1	3.3
Gearing-%	-5.7	-17.2	-16.8
Equity ratio-%	72.6	69.8	66.1
Return on investment-% (ROI)	28.3	25.9	29.7
Return on equity-% (ROE)	30.9	25.1	25.7
Undiluted earnings per share, EUR, continuing operations	0.30	0.24	0.55
Diluted Earnings per share, EUR, continuing operations	0.30	0.24	0.55
Undiluted earnings per share, EUR, discontinued operations	-0.01	0.00	0.00
Diluted Earnings per share, EUR, discontinued operations	-0.01	0.00	0.00
Equity per share, EUR	19.1	2.01	1.91
Average no. of employees, continuing operations	208	212	209
Cash flow from operating activities	1.1	2.7	5.5
Cash flow from discontinued activities	0.2	-0.6	-0,1
Cash flow from investing activities	-0.6	-0.3	0.1
Net cash used in financing activities	-2.6	-2.3	-5.9
Total cash flow	-1.9	-0.5	-0.4
CONSOLIDATED COMPREHENSIVE	1-6/2014	1-6/2013	1-12/2013
INCOME STATEMENT (MEUR)			
NET SALES	13.0	12.7	25.7
Other operating income	0.0	0.0	0.1
Materials and services	-3.2	-3.2	-6.5

Employee benefits	-4.5	-4.3	-8.9
Depreciation/amortization	-0.3	-0.3	-0.7
Other operating expenses	-2.4	-2.3	-4.2
OPERATING PROFIT, CONTINUING OPERATIONS	2.6	2.6	5.6
Share of associates' results	0.0	0.0	0.0
Financial expenses (net)	0.0	0.0	-0.1
PRE-TAX PROFIT, CONTINUING OPERATIONS	2.6	2.6	5.6
Income tax expense	-0.3	-0.7	-0.1
Net profit from continuing operations	2.3	1.9	5.5
Net profit from discontinued operations	-0.1	0.0	-1.1
NET PROFIT	2.2	1.9	4.3
Other comprehensive income items	0.0	0.0	0.0
Income tax expense for comprehensive income	0.0	0.0	0.0
Other comprehensive income items			
after taxes	0.0	0.0	0.0
TOTAL COMPREHENSIVE INCOME	2.2	1.9	4.3
Net profit attributable to:			
Parent company shareholders	2.2	1.9	4.3
Total comprehensive income attributable to:			
Parent company shareholders	2.2	1.9	4.3
Earnings per share, undiluted, EUR, continuing operations	0.30	0.24	0.55
Earnings per share, diluted, EUR, continuing operations	0.30	0.24	0.55
Earnings per share, undiluted, EUR, discontinued operations	-0.01	0.00	0,00
Earnings per share, diluted, EUR, discontinued operations	-0.01	0.00	0,00

INCOME STATEMENT (MEUR)	Q2/2014	Q2/2013
NET SALES	6.8	6.4
Other operating income	0.0	0.0
Materials and services	-1.8	-1.5
Employee benefits	-2.2	-2.2
Depreciation/amortization	-0.2	-0.2
Other operating expenses	-1.2	-1.1

OPERATING PROFIT, CONTINUING OPERATIONS	1.4	1.5
Share of associates' results	0.0	0.0
Financial expenses (net)	0.0	0.0
PRE-TAX PROFIT, CONTINUING OPERATIONS	1.4	1.4
Income tax expense	-0.1	-0.4
Net profit from continuing operations	1.3	1.0
Net profit from discontinued operations	-0.1	0.0
NET PROFIT	1.2	1.0
Other comprehensive income items	0.0	0.0
Income tax expense for comprehensive income	0.0	0.0
Other comprehensive income items after taxes	0.0	0.0
TOTAL COMPREHENSIVE INCOME	1.2	1.0
Net profit attributable to:		
Parent company shareholders	1.2	1.0
Total comprehensive income attributable to:		
Parent company shareholders	1.2	1.0

CONSOLIDATED BALANCE SHEET
(MEUR)

30 June 2014 30 June 2013 31 Dec 2013

ASSETS

NON-CURRENT ASSETS

Property, plant and equipment	1.3	1.5	1.3
Goodwill	7.0	8.1	7.0
Intangible assets	2.7	0.6	2.4
Shares in associates	0.0	0.0	0.0
Deferred tax assets	0.6	0.9	0.5
TOTAL NON-CURRENT ASSETS	11.6	11.2	11.3

CURRENT ASSETS

Inventories	1.2	1.7	1.1
Trade and other receivables	4.8	4.3	4.5
Cash and cash equivalents	2.7	4.5	4.6
TOTAL CURRENT ASSETS	8.7	10.5	10.2
Non-current assets held for sale	1.1	1.7	1.2

TOTAL ASSETS	21.4	23.3	22.6
LIABILITIES AND SHAREHOLDERS' EQUITY			
SHAREHOLDERS' EQUITY			
Share capital	5.3	5.3	5.3
Share premium	2.4	2.4	2.4
Fair value reserve	0.3	0.3	0.3
Invested unrestricted capital reserve	4.9	7.8	4.5
Retained earnings/loss	2.2	0.0	2.4
TOTAL EQUITY. attributable to holders			
of parent company equity	15.1	15.8	15.0
TOTAL SHAREHOLDERS' EQUITY	15.1	15.8	15.0
LIABILITIES			
NON-CURRENT LIABILITIES			
Deferred tax liabilities	0.0	0.2	0.1
Provisions	0.1	0.1	0.1
Financial liabilities	1.3	1.0	1.3
TOTAL LONG-TERM LIABILITIES	1.4	1.3	1.6
CURRENT LIABILITIES			
Advance payments	0.7	0.8	1.3
Trade and other payables	3.2	3.6	3.5
Financial liabilities	0.6	0.8	0.8
TOTAL SHORT-TERM LIABILITIES	4.5	5.2	5.6
Long-term liabilities held			
for sale	0.4	1.1	0.5
TOTAL LIABILITIES	6.3	7.6	7.7
TOTAL LIABILITIES AND			
SHAREHOLDERS' EQUITY	21.4	23.3	22.6

CONSOLIDATED STATEMENT OF CHANGE IN EQUITY (MEUR)

	Share capital	Share Premium	Other Reserves	Retained Earnings	Total Equity
Balance 1 Jan 2014	5.3	2.4	4.8	2.4	15.0
Dividend distribution	0.0	0.0	0.0	-2.2	-2.2
Options expense					

adjustment	0.0	0.0	0.0	0.1	0.1
Net profit	0.0	0.0	0.0	2.3	2.3
Balance 30 June 2014	5.3	2.4	4.8	2.6	15.1
	Share	Share	Other	Retained	Total
	capital	Premium	Reserves	Earnings	Equity
Balance 1 Jan 2013	5.3	2.4	7.4	-0.4	14.7
Dividend distribution	0.0	0.0	0.0	-1.6	-1.6
Used option rights	0.0	0.0	0.8	0.0	0.8
Net profit	0.0	0.0	0.0	1.9	1.9
Balance 30 June 2013	5.3	2.4	8.2	-0.1	15.8

CONSOLIDATED CASH FLOW STATEMENT (MEUR)	1-6/2014	1-6/2013	1-12/2013
Net profit	2.2	1.9	4.3
Adjustments to net profit	0.6	1.4	0.9
Change in working capital	-1.4	-0.6	0.3
Interest paid	-0.3	0.0	0.0
Interest received	0.0	0.0	0.0
CASH FLOW FROM OPERATING ACTIVITIES	1.1	2.7	5.5
Cash flow from discontinued operations	0.2	-0.6	-0.1
Sales of subsidiaries and associates' shares (net)	0.0	0.0	1.7
Purchase of subsidiary companies	0.0	0.0	-0.7
Purchase of PPE	-0.1	-0.3	-0.3
Purchase of Intangible assets	-0.5	0.0	-0.6
NET CASH USED IN INVESTING ACTIVITIES	-0.6	-0.3	0.1
Used options rights	0.1	0.8	0.8
Paid dividends and repayments of capital	-2.4	-1.6	-4.8
Repayments of long-term borrowings	0.0	-1.4	-1.7
Long-term loans received	-0.3	0.0	0.0
Finance lease principal payment	0.0	-0.1	-0.1
Loans for associated companies granted	0.0	0.0	-0.0
NET CASH USED IN FINANCING ACTIVITIES	-2.6	-2.3	-5.9
Net change in cash and equivalents	-1.9	-0.5	-0.4
Cash and equivalents. period-start	4.6	5.0	5.0

Cash and equivalents. period-end	2.7	4.5	4.6
----------------------------------	-----	-----	-----

NET SALES AND OPERATING PROFIT BY QUARTER (MEUR)

	Q2/2014	Q1/2014	Q4/2013	Q3/2013	Q2/2013	Q1/2013
Net sales	6.8	6.3	7.2	5.8	6.4	6.4
Oper. Profit	1.4	1.2	1.7	1.4	1.5	1.1
Oper. profit.-%	21	19	23	23	23	18

MAIN SHAREHOLDERS 30 June 2014

	No. of shares	%
1. Merivirta Jyri	950,000	12 %
2. Joensuun Kauppa ja Kone Oy	441,509	6 %
3. Eyemaker's Finland Oy	350,000	4 %
4. Gerako Oy	350,000	4 %
5. Sijoitusrahasto Evli Suomi Osake	338,087	4 %
6. Keskinäinen Eläkevakuutusyhtiö Etera	265,000	3 %
7. Alpisalo Mia	211,949	3 %
8. Sijoitusrahasto Danske Suomi kasvuosake	150,000	2 %
9. Salovaara Olli-Pekka	109,207	1 %
10. Kirkon Keskusrahasto	92,569	1 %

Revenio Group Corporation
Board of Directors

For additional information:

President & CEO Olli-Pekka Salovaara, tel. +358 40 567 5520
olli-pekka.salovaara@revenio.fi
<http://www.revenio.fi>

DISTRIBUTION:

NASDAQ OMX Helsinki
Financial Supervisory Authority (FIN-FSA)
Principal media
www.revenio.fi

The Revenio Group in brief

Revenio is a Finnish health tech group whose core business is tonometers. The Revenio Health Tech segment comprises the business operations of Icare Finland Oy. The widely patented Icare product family is the current cornerstone of the Group's success. Revenio seeks vigorous growth in health technology, both organically and through acquisitions and mergers.

The Revenio Group also includes other business operations, which are grouped under the Technology and Services segment. This segment's operations have a shared global market and represent the cutting edge of technology products and services in their industry. These businesses are profitable in their industries

and generate positive cash flow.

In 2013, the Revenio Group's net sales totaled EUR 25.7 million, with its operating margin standing at 21.7 %. The Revenio Group Corporation is listed on NASDAQ OMX Helsinki.

[HUG#1846094]

This news release was distributed by GlobeNewswire, www.globenewswire.com – a Nasdaq company